Table I.
Main characteristics and findings of studies.
| Study | Setting | N | Age, years ± SD (range) | Males (%) | Prevalence of DM/CVD/PD (%) | Median (range) SOFA/PaO2/FiO2 | Antithrombotic treatment dosing | Prevalence of DVT/PE (%) | D‐dimer (μg/ml; median values) and predictive value (ratio and 95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Stoneham et al. 3 | General ward | 274 | VTE 67 ± 12 | VTE 67 | VTE 38/29/38 | NR | NR | 2/6 |
VTE vs. non‐VTE: 4·1 vs. 1·2 Adjusted OR for VTE: 1·4 (1·2,1·8) |
| Wright et al. 4 | ICU | 44 | 54 (19–86) | 64 | 41/NR/14 | 8 (7–10)/163 (127–235) | Prophylactic | 25/0 | 1·8 (0·9–4·1) |
| Thomas et al. 5 | ICU | 63 | 59 ± 13 | 69 | NR | NR | Prophylactic | 2/8 | 0·4 (0·1–3·6) |
| Middeldorp et al. 6 | General ward 62%; ICU 38% | 198 | 61 ± 14 | 66 | NR | NR | Mainly prophylactic | 13/7 |
VTE vs. non‐VTE: 2·6 vs. 1·0 Subhazard ratio for VTE: 1·4 (1·1,1·9) |
| Helms et al. 7 | ICU | 150 | 63 (53–71) | 81 | 20/48/14 | 8 (5–10)/125 (97–170) | Mainly prophylactic | 2/17 | 2·3 (1·2–20·0) |
| Lodigiani et al. 8 | General ward 84%; ICU 16% | 388 | 66 (55–85) | 68 | 23/33/9 | NR | Mixed doses | 2/3 | Rapid increase in D‐dimer in non‐survivors |
| Poissy et al. 9 | ICU | 107 | PE 57 (29–80) | PE 59 | NR |
PE 4 (0–4)/NR |
Prophylactic | 5/21 | Subhazard ratio for PE: 1·8 (1·0,3·2) |
| Tavazzi et al. 10 | ICU | 54 | VTE 68 ± 7 | NR | NR | NR | Prophylactic | 15/6 | NR |
| Llitjos et al. 11 | ICU | 26 | 68 (52–75) | 77 | NR | 3 (2–5)/87 (74–116) | Mainly therapeutic | 54/23 | 1·8 (1·1–2·9) |
| Beun et al. 12 | ICU | 75 | NR | NR | NR | NR | NR | 4/27 | NR |
| Klok et al. 13 | ICU | 184 | 64 ± 12 | 76 | NR | NR | Mainly prophylactic | 2/35 | NR |
CI, confidence intervals; CVD, cardiovascular disease; DM, diabetes mellitus; DVT, deep vein thrombosis; FiO2, fraction of inspired oxygen; ICU, intensive care unit; NR, not reported; OR, odds ratio; PaO2, arterial partial pressure of oxygen; PD, pulmonary disease; PE, pulmonary embolism; SD, standard deviation; SOFA, Sequential Organ Failure Assessment; VTE, venous thromboembolic events.